VERU INC. Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount
VERU INC. (VERU) had Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount of $0 as of 2021-09-30, per its 10-K filed 2021-12-02.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount · last filed 2021-12-02
- 2021-09-30: Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount $0.00.
- 2020-09-30: Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount $0.00.
- 2020-06-30: Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount $0.00.
- 2020-03-31: Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount $0.00.
| Period end | Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount |
|---|---|
| 2021-09-30 | $0.00 10-K · filed 2021-12-02 |
| 2020-09-30 | $0.00 10-K · filed 2021-12-02 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-13 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-13 |
| 2019-12-31 | $0.00 10-Q · filed 2020-02-12 |
| 2019-09-30 | $0.00 10-K · filed 2020-12-10 |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-13 |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-13 |
| 2018-12-31 | $0.00 10-Q · filed 2020-02-12 |
| 2018-09-30 | $0.00 10-K · filed 2018-12-13 |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-08 |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |